Tumor-associated antigen-Major Histocompatibility Complex complex on dendritic cells (TAA-MHC-DC complex)

Tumor-associated antigens (TAAs) presented by Major Histocompatibility Complex (MHC) molecules on dendritic cells (DCs) represent a critical interface in cancer immunotherapy [Nature Reviews Immunology, 2004]. Dendritic cells, as professional antigen-presenting cells, capture TAAs from the tumor microenvironment, process them into short peptides, and display them on their surface via MHC Class I and Class II molecules [Janeway's Immunobiology]. This presentation is the primary signal required for the priming and activation of naive T cells into effector cytotoxic T lymphocytes (CTLs) and helper T cells, which then orchestrate a targeted attack against malignant cells [Cell, 2001]. Therapeutic strategies, such as dendritic cell vaccines (e.g., Sipuleucel-T), involve loading DCs with specific TAAs to enhance this presentation and overcome tumor-induced immunosuppression [NEJM, 2010]. The success of these therapies depends on the efficient recognition of the TAA-MHC complex by the T-cell receptor (TCR), making it a central target for inducing long-lasting anti-tumor immunity [PubMed, 2021]. However, challenges such as MHC downregulation by tumors and the presence of an immunosuppressive microenvironment can hinder the effectiveness of targeting this complex [Nature, 2011].

Other names

Tumor antigen-MHC complexDendritic cell-presented tumor antigensPeptide-MHC complex on APCsTAA-HLA complexpMHC complex on dendritic cells

Dendritic cells process tumor-associated antigens into peptides and present them via MHC molecules to T-cell receptors (TCRs), initiating a specific cytotoxic T-lymphocyte (CTL) response against tumor cells [Nature Reviews Cancer, 2004].